Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations

NCT01827267 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT01827267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01827267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
Lead sponsor
Puma Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2013
Completion date
October 6, 2017
Enrollment
62 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

her2-mutant non-small cell lung cancer